Overview |  Funded R&D |  Library Licensing |  Patent Licensing |  In-Licensing

Dyax offers extensive licensing options to its collaborators, as part of its Licensing and Fund Research Program (LFRP), as well as co-development and in-licensing opportunities. Collaborators can benefit from the application of the same phage display technology and automation Dyax applies to its own biotherapeutic pursuits.

As a fully integrated biotechnology company, Dyax is able to independently advance a compound from the initial stages of discovery and lead identification, through preclinical testing, and ultimately through clinical development and commercialization. All of these stages can be accomplished on collaborators’ behalf as well.

Dyax's own focus is on the development of fully human monoclonal antibodies, small proteins and peptides as novel biotherapeutics.

On behalf of our external collaborators, we offer biotherapeutic development capabilities, and also extend our reach into non-core areas such as imaging, diagnostics, research reagents, and affinity purification.

Working Together
Agreements with Dyax through the LFRP, co-development and in-licensing programs can be structured in a variety of ways, from more simple patent licenses and library licenses, to more involved funded research and/or co-development agreements. Agreement alternatives include:

1. Co-development partnerships with other companies
2. In-licensing of novel targets from companies and academic institutions
3. Funded research to discover and develop biotherapeutics on behalf of other companies
4. Library licensing to allow a company to discover and develop biotherapeutics in house via access to Dyax's antibody, peptide, and protein phage display libraries. These libraries may also be licensed in areas outside Dyax's strategic focus, such as in vitro and in vivo diagnostics, research reagents, and the affinity purification of pharmaceuticals.
5. Patent licensing of phage display patents to other companies and academic institutions.

Contact our